E-LIB Suche - Ergebnisse für: Katharina Schwarze

1

ATIM-38. GLITIPNI: A PHASE 1B CLINICAL TRIAL COMBINING SURG..:

Duerinck, Johnny ; Awada, Gil ; Katharina Schwarze, Julia...
Neuro-Oncology. 21 (2019) Supplement_6 - p. vi10-vi10 , 2019

Link: https://doi.org/10.1093/..

2

SCIDOT-30. GLITIPNI: A PHASE 1B CLINICAL TRIAL COMBINING SU..:

Duerinck, Johnny ; Awada, Gil ; Katharina Schwarze, Julia...
Neuro-Oncology. 21 (2019) Supplement_6 - p. vi277-vi278 , 2019

Link: https://doi.org/10.1093/..

3

Preference-Based Implementation of Video Consultations in U..:

Kleinschmidt, Lara ; Walendzik, Anke ; Wasem, Jürgen...
JMIR Research Protocols. 13 (2024) - p. e50932 , 2024

Link: https://doi.org/10.2196/..

4

Design and implementation of ParkinsonAKTIV: an interventio..:

Achtert, Katharina ; Huchtemann, Tessa ; Altendorf, Maria...
Neurological Research and Practice. 5 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

5

Effectiveness and costs of a low-threshold hearing screenin..:

Schwarze, Katharina ; Mathmann, Philipp ; Schäfer, Karolin...
BMJ Open. 13 (2023) 5 - p. e070259 , 2023

Link: https://doi.org/10.1136/..

6

The complete costs of genome sequencing: a microcosting stu..:

Schwarze, Katharina ; Buchanan, James ; Fermont, Jilles M....
Genetics in Medicine. 22 (2020) 1 - p. 85-94 , 2020

Link: https://doi.org/10.1038/..

7

Are whole-exome and whole-genome sequencing approaches cost..:

Schwarze, Katharina ; Buchanan, James ; Taylor, Jenny C..
Genetics in Medicine. 20 (2018) 10 - p. 1122-1130 , 2018

Link: https://doi.org/10.1038/..

8

Design and implementation of ParkinsonAKTIV: an interventio..:

Katharina Achtert ; Tessa Huchtemann ; Maria Altendorf...
https://doi.org/10.1186/s42466-023-00249-5. , 2023

Link: https://doi.org/10.1186/..

9

Effectiveness and costs of a low-threshold hearing screenin..:

Werner Brannath ; Anja Neumann ; Katharina Schwarze...
https://bmjopen.bmj.com/content/13/5/e070259.full. , 2023

Link: https://doi.org/10.1136/..

10

Intratumoral administration of the immunologic adjuvant AS0..:

Tijtgat, Jens ; Geeraerts, Xenia ; Boisson, Anais...
Journal for ImmunoTherapy of Cancer. 12 (2024) 1 - p. e008148 , 2024

Link: https://doi.org/10.1136/..

11

A randomized phase II clinical trial of stereotactic body r..:

Vounckx, Manon ; Tijtgat, Jens ; Stevens, Latoya...
Cancer Immunology, Immunotherapy. 73 (2024) 9 - p. , 2024

Link: https://doi.org/10.1007/..

12

BIOM-39. P-ERK ASSOCIATION WITH OVERALL SURVIVAL IN RECURRE..:

Arrieta, Victor ; Duerinck, Johnny ; Burdett, Kirsten B...
Neuro-Oncology. 24 (2022) Supplement_7 - p. vii13-vii13 , 2022

Link: https://doi.org/10.1093/..

13

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant T..:

Schwarze, Julia Katharina ; Garaud, Soizic ; Jansen, Yanina J. L....
Cancers. 14 (2022) 3 - p. 682 , 2022

Link: https://doi.org/10.3390/..

14

CTIM-12. A PHASE I CLINICAL TRIAL ON THE INTRACRANIAL ADMIN..:

Geens, Wietse ; Schwarze, Julia Katharina ; Tijtgat, Jens...
Neuro-Oncology. 24 (2022) Supplement_7 - p. vii62-vii62 , 2022

Link: https://doi.org/10.1093/..

15

Intratumoral administration of CD1c (BDCA-1)+and CD141 (BDC..:

Schwarze, Julia Katharina ; Tijtgat, Jens ; Awada, Gil...
Journal for ImmunoTherapy of Cancer. 10 (2022) 9 - p. e005141 , 2022

Link: https://doi.org/10.1136/..